Leinco Technologies

Anti-Human Vascular Endothelial Growth Factor

Product Code:
 
LEI-V111
Product Group:
 
Primary Antibodies
Host Type:
 
Mouse
Antibody Isotype:
 
IgG2a
Antibody Clonality:
 
Monoclonal
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Western Blot (WB)
Shipping:
 
Ambient
Storage:
 
This lyophilized mon°Clonal antibody should be stored desiccated at -20°C. For long-term storage of the reconstituted antibody aseptically aliquot into working volumes and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-V111-500ug500 ug£458.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This purified monoclonal antibody is aseptically filtered and lyophilized from PBS with no carrier proteins or preservatives added.
Formulation:
This purified monoclonal antibody is aseptically filtered and lyophilized from PBS with no carrier proteins or preservatives added.
Immunogen:
Purified Recombinant Human VEGF (>98%)
Long Description:
Vascular endothelial growth factor (VEGF), a potent proangiogenic cytokine1 is the key signal used by oxygen-hungry cells to promote growth of blood vessels. It binds to specialized receptors on the surfaces of endothelial cells and directs them to build new vessels.2 VEGF are crucial regulators of vascular development during embryogenesis (vasculogenesis) and blood-vessel formation in the adult (angiogenesis). Abnormal VEGF function is associated with inflammatory diseases including atherosclerosis, and hyperthyroidism.3,4,5,6
Target:
Vascular Endothelial Growth Factor

References

1. Folkman J et al. (2008) FASEB J. 22: 3728 2. Goodsell DS et al. (2002) The Oncologist 7: 569 3. Mugishima H. et al. (2006) J Atheroscler Thromb. 13: 130 4. Claesson-Welsh L et al. (2006) Exp Cell Res. 312: 549 5. Claesson-Welsh L et al. (1999) Trends Biochem Sci. 28: 488 6. Ellis LM et al. (2005) J Clin Oncol. 23: 1011